查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2000407

仿生系统市场预测至2034年：按产品、器官类型、组件、材料、应用和地区分類的全球分析

Microphysiological Systems Market Forecasts to 2034 - Global Analysis By Product, By Organ Type, By Component, By Material, By Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球仿生系统（器官晶片）市场规模将达到 3.0761 亿美元，并在预测期内以 35.2% 的复合年增长率增长，到 2034 年将达到 4.4833 亿美元。

仿生系统（器官晶片）是一种先进的微流体装置，它利用置于人工建造环境中的活细胞来复製人体器官的结构和功能。这些系统能够模拟血液流动、机械力以及细胞间相互作用等生理条件，进而建构出肺、肝、心臟和大脑等器官的逼真模型。它们被广泛应用于药物研发、毒性测试和疾病建模。透过提供与人体相关的生物学讯息，器官晶片平台能够减少对动物实验的依赖，提高临床前试验的预测准确性，并加速药物研发和个人化医疗的发展。

对先进药物检测的需求日益增长

传统的动物模型和二维细胞培养往往无法复製人体生理反应，导致临床试验中药物失败率居高不下。器官晶片技术提供了一个微工程环境，能够模拟人体器官的结构和功能。这使得研究人员能够在临床试验前更好地评估药物的毒性、疗效和药物动力学。製药公司正越来越多地采用这些系统来降低研发成本并提高成功率。随着製药业致力于更安全、更快速的药物研发，对先进测试平台的需求也持续成长。

缺乏标准化的检验通讯协定

晶片设计、细胞来源和调查方法在不同的研究机构和公司之间往往存在差异。这种缺乏统一标准的现状使得不同实验室之间的结果难以比较。监管机构在药物核准过程中也要求提供一致的检验资料才能核准器官晶片系统。如果没有全球认可的测试框架，製药公司可能会犹豫是否将这些系统全面整合到其研发管线中。因此，监管方面的明确规定和标准化的指导方针对于器官晶片系统的广泛市场应用至关重要。

与人工智慧驱动的药物发现相结合

人工智慧技术能够分析微生理系统产生的复杂生物数据，从而更准确地预测药物反应。将人工智慧与晶片器官平台结合，可实现高通量筛检并改善疾病机制的建模。这种方法使研究人员能够更快地识别有前景的候选药物，同时减少实验误差。人工智慧驱动的分析也有助于晶片设计和实验参数的最佳化。随着製药公司越来越多地采用数位化和数据驱动的研究方法，人工智慧与晶片器官技术的协同效应有望加速创新。

与传统细胞培养模型的竞争

传统方法应用广泛、成本低廉，且为所有实验室的研究人员所熟知。许多製药公司已经拥有围绕二维和三维细胞培养系统的基础设施和专业技术。过渡到器官晶片平台可能需要在设备和培训方面进行额外投资。此外，一些早期研究应用可能仍然依赖更易于实施的简单模型。这种对传统模型的持续依赖可能会减缓微生理系统的应用普及。

新冠疫情的影响：

新冠疫情对仿生系统市场产生了复杂但最终的正面影响。疫情期间，研究人员寻求先进的模型来研究病毒感染并评估潜在的治疗方法。器官晶片平台被用来模拟人类肺部和免疫系统对SARS-CoV-2的反应。这加速了人们对仿生技术的研究兴趣和投资。然而，供应链中断和实验室的暂时关闭最初减缓了研究活动。资金筹措重点也转向了与疫情相关的计划。

在预测期内，肝臟晶片细分市场预计将占据最大的市场份额。

肝臟在药物代谢和毒性评估中发挥着至关重要的作用，因此，预计在预测期内，肝臟晶片将占据最大的市场份额。製药公司在药物研发的早期阶段就将肝毒性评估放在首位。肝臟晶片模型能够忠实地模拟人类肝臟的超微结构和生化反应。与传统的细胞培养相比，这些系统使研究人员能够更精确地研究代谢交互作用和药物的长期效应。临床试验中药物性肝损伤的高发生率进一步推动了对可靠肝臟模型的需求。

在预测期内，个人化医疗领域预计将呈现最高的复合年增长率。

在预测期内，由于人们对以患者为中心的治疗方案日益关注，因此个人化医疗领域预计将呈现最高的成长率。器官晶片平台能够整合来自个别患者的细胞，从而更精确地模拟疾病状态。这使得研究人员能够评估不同患者对特定药物和治疗方法的反应。这种能力在癌症和神经系统疾病等复杂疾病中尤其重要。製药公司和研究机构正加大对个人化疗法研发的投入。

市占率最大的地区：

在预测期内，北美预计将占据最大的市场份额，这主要得益于其强大的研究基础设施和对生物医学创新的巨额投资。该地区汇聚了许多主要企业、製药公司和学术研究机构。政府机构和私人投资者正积极资助与先进药物检测技术相关的研究。此外，大学与产业界的合作正在加速器官晶片平台的技术进步。主要市场参与企业的加入也进一步推动了该地区的成长。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于药物研发活动的增加和生技产业的扩张。中国、日本、韩国和印度等国家正在生命科学研究基础建设进行大量投资。全球製药公司与区域研究机构之间合作的加强也促进了市场扩张。该地区各国政府正透过资助计画和生物技术相关措施支持创新。此外，对先进药物检测技术日益增长的需求也推动了器官晶片系统的应用。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域划分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章：执行摘要

  • 市场概览及主要亮点
  • 成长动力、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球仿生系统市场：依产品划分

  • 单一器官晶片系统
  • 多重器官（晶片人体）系统
  • 疾病特异性晶片模型
  • 高通量筛检平台
  • 整合器官晶片工作站
  • 模组化和可自订的晶片平台
  • 其他产品

第六章 全球仿生系统市场：依器官类型划分

  • 肝片
  • 心形晶片
  • 肺晶片
  • 肾形片
  • 皮肤和屏障模型
  • 其他器官类型

第七章 全球仿生系统市场：依组件划分

  • 微流体晶片
  • 细胞株和类器官
  • 试剂和培养基
  • 泵浦和流量控制设备
  • 其他规则

第八章：全球仿生系统市场：依材料划分

  • PDMS
  • 热塑性塑料
  • 玻璃基晶片
  • 基于硅的平台
  • 水凝胶基质
  • 其他材料

第九章 全球仿生系统市场：依应用划分

  • 药物发现与筛检
  • 毒性测试
  • 疾病模型
  • 个人化医疗
  • 其他用途

第十章：全球仿生系统市场：依地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟、合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • Emulate, Inc.
  • CN Bio Innovations Ltd.
  • MIMETAS BV
  • TissUse GmbH
  • InSphero AG
  • AxoSim, Inc.
  • Kirkstall Ltd.
  • Nortis Inc.
  • AlveoliX AG
  • Hesperos, Inc.
  • Cherry Biotech
  • Altis Biosystems
  • NETRI
  • Draper Laboratory
  • Organovo Holdings, Inc.
Product Code: SMRC34504

According to Stratistics MRC, the Global Microphysiological Systems (Organ-on-a-Chip) Market is accounted for $307.61 million in 2026 and is expected to reach $448.33 million by 2034 growing at a CAGR of 35.2% during the forecast period. Microphysiological Systems (Organ-on-a-Chip) are advanced microfluidic devices that replicate the structure and function of human organs using living cells arranged in engineered environments. These systems simulate physiological conditions such as blood flow, mechanical forces, and cellular interactions, enabling realistic models of organs like the lung, liver, heart, or brain. They are widely used in drug discovery, toxicity testing, and disease modeling. By providing human-relevant biological insights, organ-on-a-chip platforms reduce reliance on animal testing, improve predictive accuracy in preclinical studies, and accelerate pharmaceutical research and personalized medicine development.

Market Dynamics:

Driver:

Rising demand for advanced drug testing

Traditional animal models and 2D cell cultures often fail to replicate human physiological responses, leading to high drug failure rates during clinical trials. Organ-on-a-chip technologies provide microengineered environments that mimic the structure and function of human organs. This enables researchers to better evaluate drug toxicity, efficacy, and pharmacokinetics before clinical testing. Pharmaceutical companies are increasingly adopting these systems to reduce development costs and improve success rates. As the pharmaceutical industry focuses on safer and faster drug development, demand for advanced testing platforms continues to grow.

Restraint:

Lack of standardized validation protocols

Different research institutions and companies often use varied chip designs, cell sources, and testing methodologies. This lack of uniform standards makes it difficult to compare results across laboratories. Regulatory agencies also require consistent validation data before accepting organ-on-chip systems for drug approval processes. Without globally accepted testing frameworks, pharmaceutical companies may hesitate to fully integrate these systems into their pipelines. The need for regulatory clarity and standardized guidelines is therefore critical for widespread market adoption.

Opportunity:

Integration with AI-driven drug discovery

AI technologies can analyze complex biological data generated from microphysiological systems to predict drug responses more accurately. Combining AI with organ-on-chip platforms enables high-throughput screening and improved modeling of disease mechanisms. This approach helps researchers identify promising drug candidates faster while reducing experimental errors. AI-powered analytics can also optimize chip design and experimental parameters. As pharmaceutical companies increasingly adopt digital and data-driven research methods, the synergy between AI and organ-on-chip technology is expected to accelerate innovation.

Threat:

Competition from traditional cell culture models

Conventional methods are widely established, inexpensive, and familiar to researchers across laboratories. Many pharmaceutical companies already have infrastructure and expertise built around 2D and 3D cell culture systems. Transitioning to organ-on-chip platforms may require additional investment in equipment and training. Furthermore, some early-stage research applications may still rely on simpler models that are easier to implement. This ongoing reliance on conventional models may slow the widespread adoption of microphysiological systems.

Covid-19 Impact:

The COVID-19 pandemic had a mixed but overall positive impact on the Microphysiological Systems market. During the pandemic, researchers sought advanced models to study viral infections and evaluate potential therapeutics. Organ-on-chip platforms were used to replicate human lung and immune responses to SARS-CoV-2. This accelerated research interest and investment in microphysiological technologies. However, supply chain disruptions and temporary laboratory shutdowns initially slowed research activities. Funding priorities also shifted toward pandemic-related projects.

The liver-on-a-chip segment is expected to be the largest during the forecast period

The liver-on-a-chip segment is expected to account for the largest market share during the forecast period as the liver plays a crucial role in drug metabolism and toxicity assessment. Pharmaceutical companies prioritize evaluating hepatotoxicity early in the drug development process. Liver-on-chip models closely mimic human liver microarchitecture and biochemical responses. These systems allow researchers to study metabolic interactions and long-term drug effects more accurately than traditional cell cultures. The high incidence of drug-induced liver injury in clinical trials further drives demand for reliable liver models.

The personalized medicine segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the personalized medicine segment is predicted to witness the highest growth rate due to increasing interest in patient-specific treatment approaches. Organ-on-chip platforms can incorporate cells derived from individual patients to model disease conditions more precisely. This enables researchers to evaluate how different patients respond to specific drugs or therapies. Such capabilities are particularly valuable in complex diseases like cancer and neurological disorders. Pharmaceutical companies and research institutions are increasingly investing in personalized treatment development.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong research infrastructure and high investment in biomedical innovation. The region hosts many leading biotechnology firms, pharmaceutical companies, and academic research institutions. Government agencies and private investors actively fund research related to advanced drug testing technologies. Additionally, collaborations between universities and industry players accelerate technological advancements in organ-on-chip platforms. The presence of major market participants further strengthens regional growth.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by increasing pharmaceutical research activities and expanding biotechnology sectors. Countries such as China, Japan, South Korea, and India are investing heavily in life science research infrastructure. Growing collaborations between global pharmaceutical companies and regional research institutions also contribute to market expansion. Governments in the region are supporting innovation through funding programs and biotechnology initiatives. Additionally, the rising demand for advanced drug testing technologies is boosting adoption of organ-on-chip systems.

Key players in the market

Some of the key players in Microphysiological Systems (Organ-on-a-Chip) Market include Emulate, Inc., CN Bio Innovations Ltd., MIMETAS BV, TissUse GmbH, InSphero AG, AxoSim, Inc., Kirkstall Ltd., Nortis Inc., AlveoliX AG, Hesperos, Inc., Cherry Biotech, Altis Biosystems, NETRI, Draper Laboratory and Organovo Holdings, Inc.

Key Developments:

In June 2025, Emulate launched the AVA Emulation System, a high-throughput benchtop instrument that automates the culture, incubation, and real-time imaging of up to 96 independent Organ-Chip samples simultaneously. The system utilizes the new Chip-Array consumable and is designed to integrate with standard laboratory workflows, reducing consumable costs by four-fold and hands-on time by more than half compared to previous technologies.

In April 2025, CN Bio entered a long-term strategic partnership with Pharmaron to validate and integrate its PhysioMimix(R) OOC technology into Pharmaron's global R&D platform, focusing on disease modelling, toxicity testing, and ADME studies . The agreement includes the installation of PhysioMimix instruments at Pharmaron's global facilities to co-develop new applications addressing unmet needs in drug discovery.

Products Covered:

  • Single-Organ-on-a-Chip Systems
  • Multi-Organ (Body-on-a-Chip) Systems
  • Disease-Specific Chip Models
  • High-Throughput Screening Platforms
  • Integrated Organ-on-Chip Workstations
  • Modular & Customizable Chip Platforms
  • Other Products

Organ Types Covered:

  • Liver-on-a-Chip
  • Heart-on-a-Chip
  • Lung-on-a-Chip
  • Kidney-on-a-Chip
  • Skin & Barrier Models
  • Other Organ Types

Components Covered:

  • Microfluidic Chips
  • Cell Lines & Organoids
  • Reagents & Media
  • Pumps & Flow Controllers
  • Other Components

Materials Covered:

  • PDMS
  • Thermoplastics
  • Glass-Based Chips
  • Silicon-Based Platforms
  • Hydrogel Matrices
  • Other Materials

Applications Covered:

  • Drug Discovery & Screening
  • Toxicology Testing
  • Disease Modeling
  • Personalized Medicine
  • Other Applications

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Product

  • 5.1 Single-Organ-on-a-Chip Systems
  • 5.2 Multi-Organ (Body-on-a-Chip) Systems
  • 5.3 Disease-Specific Chip Models
  • 5.4 High-Throughput Screening Platforms
  • 5.5 Integrated Organ-on-Chip Workstations
  • 5.6 Modular & Customizable Chip Platforms
  • 5.7 Other Products

6 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Organ Type

  • 6.1 Liver-on-a-Chip
  • 6.2 Heart-on-a-Chip
  • 6.3 Lung-on-a-Chip
  • 6.4 Kidney-on-a-Chip
  • 6.5 Skin & Barrier Models
  • 6.6 Other Organ Types

7 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Component

  • 7.1 Microfluidic Chips
  • 7.2 Cell Lines & Organoids
  • 7.3 Reagents & Media
  • 7.4 Pumps & Flow Controllers
  • 7.5 Other Components

8 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Material

  • 8.1 PDMS
  • 8.2 Thermoplastics
  • 8.3 Glass-Based Chips
  • 8.4 Silicon-Based Platforms
  • 8.5 Hydrogel Matrices
  • 8.6 Other Materials

9 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Application

  • 9.1 Drug Discovery & Screening
  • 9.2 Toxicology Testing
  • 9.3 Disease Modeling
  • 9.4 Personalized Medicine
  • 9.5 Other Applications

10 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Emulate, Inc.
  • 13.2 CN Bio Innovations Ltd.
  • 13.3 MIMETAS BV
  • 13.4 TissUse GmbH
  • 13.5 InSphero AG
  • 13.6 AxoSim, Inc.
  • 13.7 Kirkstall Ltd.
  • 13.8 Nortis Inc.
  • 13.9 AlveoliX AG
  • 13.10 Hesperos, Inc.
  • 13.11 Cherry Biotech
  • 13.12 Altis Biosystems
  • 13.13 NETRI
  • 13.14 Draper Laboratory
  • 13.15 Organovo Holdings, Inc.

List of Tables

  • Table 1 Global Microphysiological Systems (Organ-on-a-Chip) Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Product (2023-2034) ($MN)
  • Table 3 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Single-Organ-on-a-Chip Systems (2023-2034) ($MN)
  • Table 4 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Multi-Organ (Body-on-a-Chip) Systems (2023-2034) ($MN)
  • Table 5 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Disease-Specific Chip Models (2023-2034) ($MN)
  • Table 6 Global Microphysiological Systems (Organ-on-a-Chip) Market, By High-Throughput Screening Platforms (2023-2034) ($MN)
  • Table 7 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Integrated Organ-on-Chip Workstations (2023-2034) ($MN)
  • Table 8 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Modular & Customizable Chip Platforms (2023-2034) ($MN)
  • Table 9 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Products (2023-2034) ($MN)
  • Table 10 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Organ Type (2023-2034) ($MN)
  • Table 11 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Liver-on-a-Chip (2023-2034) ($MN)
  • Table 12 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Heart-on-a-Chip (2023-2034) ($MN)
  • Table 13 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Lung-on-a-Chip (2023-2034) ($MN)
  • Table 14 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Kidney-on-a-Chip (2023-2034) ($MN)
  • Table 15 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Skin & Barrier Models (2023-2034) ($MN)
  • Table 16 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Organ Types (2023-2034) ($MN)
  • Table 17 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Component (2023-2034) ($MN)
  • Table 18 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Microfluidic Chips (2023-2034) ($MN)
  • Table 19 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Cell Lines & Organoids (2023-2034) ($MN)
  • Table 20 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Reagents & Media (2023-2034) ($MN)
  • Table 21 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Pumps & Flow Controllers (2023-2034) ($MN)
  • Table 22 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Components (2023-2034) ($MN)
  • Table 23 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Material (2023-2034) ($MN)
  • Table 24 Global Microphysiological Systems (Organ-on-a-Chip) Market, By PDMS (2023-2034) ($MN)
  • Table 25 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Thermoplastics (2023-2034) ($MN)
  • Table 26 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Glass-Based Chips (2023-2034) ($MN)
  • Table 27 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Silicon-Based Platforms (2023-2034) ($MN)
  • Table 28 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Hydrogel Matrices (2023-2034) ($MN)
  • Table 29 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Materials (2023-2034) ($MN)
  • Table 30 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Application (2023-2034) ($MN)
  • Table 31 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Drug Discovery & Screening (2023-2034) ($MN)
  • Table 32 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Toxicology Testing (2023-2034) ($MN)
  • Table 33 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Disease Modeling (2023-2034) ($MN)
  • Table 34 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Personalized Medicine (2023-2034) ($MN)
  • Table 35 Global Microphysiological Systems (Organ-on-a-Chip) Market, By Other Applications (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.